TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma
- 26 March 2013
- journal article
- research article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 20 (3) , 361-370
Abstract
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with no effective therapy for patients with unresectable disease. The aim of the current study was i) to evaluate TOP2A expression and function in human adrenocortical neoplasm and ACC cells and ii) to determine the anticancer activity of agents that target TOP2A. TOP2A mRNA and protein expression levels were evaluated in 112 adrenocortical tissue samples (21 normal adrenal cortex, 80 benign adrenocortical tumors, and 11 ACCs). In vitro siRNA knockdown of TOP2A in ACC cell lines (NCI-H295R and SW13) was used to determine its effect on cellular proliferation, cell cycle, anchorage-independent growth, and cellular invasion. We screened 14 TOP2A inhibitors for their anticancer activity in ACC cells. TOP2A mRNA and protein expression was significantly higher in ACC than in benign and normal adrenocortical tissue samples (PTOP2A gene expression in ACC cell lines significantly decreased cell proliferation, anchorage-independent growth, and invasion (PTOP2A inhibitors had antiproliferative activity, 5 of the 14 TOP2A inhibitors had a higher antiproliferative activity than mitotane, and aclarubicin was the agent with the highest activity. Aclarubicin was validated to significantly decrease proliferation and tumor spheroid size in both NCI-H295R and SW13 ACC cell lines (PTOP2A is overexpressed in ACC, regulates cellular proliferation and invasion in ACC cells, and is an attractive target for ACC therapy. Of the TOP2A inhibitors screened, aclarubicin is a good candidate agent to test in future clinical trials for patients with locally advanced and metastatic ACC.Keywords
This publication has 54 references indexed in Scilit:
- DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical TumorsThe Journal of Clinical Endocrinology & Metabolism, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Multifactorial Approach to Predicting Resistance to AnthracyclinesJournal of Clinical Oncology, 2011
- Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancerJournal of Translational Medicine, 2011
- Expression Profiling of Liposarcoma Yields a Multigene Predictor of Patient Outcome and Identifies Genes That Contribute to LiposarcomagenesisCancer Research, 2011
- Prediction of epigenetically regulated genes in breast cancer cell linesBMC Bioinformatics, 2010
- Antineoplastic Effects of Decitabine, an Inhibitor of DNA Promoter Methylation, in Adrenocortical Carcinoma CellsArchives of Surgery, 2010
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical librariesProceedings of the National Academy of Sciences, 2006
- Adrenocortical Carcinoma: Clinical UpdateThe Journal of Clinical Endocrinology & Metabolism, 2006